title: A pilot study comparing basiliximab and anti-thymocyte globulin as induction therapy in sensitized renal allograft recipients.
authors.affiliation: Service de Néphrologie Dialyse Transplantation Rénale Hôpital Nord, CHU de Saint-Etienne, France.
authors.forename: C
authors.initials: C
authors.lastname: Mariat
authors.forename: A
authors.initials: A
authors.lastname: Afiani
authors.forename: E
authors.initials: E
authors.lastname: Alamartine
authors.forename: D
authors.initials: D
authors.lastname: Thibaudin
authors.forename: J P
authors.initials: JP
authors.lastname: de Filippis
authors.forename: F
authors.initials: F
authors.lastname: Berthoux
mesh_terms: D000208:Acute Disease; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000961:Antilymphocyte Serum / Q000627:therapeutic use*; D000077552:Basiliximab; D003586:Cytomegalovirus Infections / Q000453:epidemiology; D006084:Graft Rejection / Q000453:epidemiology; D006085:Graft Survival; D006650:Histocompatibility Testing; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D015994:Incidence; D016030:Kidney Transplantation / Q000276:immunology* / Q000379:methods; D010865:Pilot Projects; D011183:Postoperative Complications / Q000145:classification / Q000453:epidemiology; D011993:Recombinant Fusion Proteins
chemical_list: D000911:Antibodies, Monoclonal; D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D011993:Recombinant Fusion Proteins; D000077552:Basiliximab